Overall, 27 patients (38.0%) receiving capivasertib–fulvestrant and 23 patients (36.5%) receiving placebo–fulvestrant had been previously treated with CDK4/6 inhibitor for advanced breast cancer (Table 1). This evidence concerns the gene CDK4 and breast carcinoma.